ArticleAmerican journal of translational research2017
Interleukin-25 enhances the capacity of mesenchymal stem cells to induce intestinal epithelial cell regeneration.
Article in American journal of translational research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Therapeutic Prospects of Mesenchymal Stem Cell and Their Derived Exosomes in the Regulation of the Gut Microbiota in Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Mechanism of Acupuncture and Moxibustion on Promoting Mucosal Healing in Ulcerative Colitis.Chinese journal of integrative medicine · 2023Review
- Research progress of engineered mesenchymal stem cells and their derived exosomes and their application in autoimmune/inflammatory diseases.Stem cell research & therapy · 2023Review
- Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.European journal of medical research · 2023Review
- Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.World journal of stem cells · 2022Review
- Interleukin 25 and its biological features and function in intestinal diseases.Central-European journal of immunology · 2022Review
- Type 2 immunity in intestinal homeostasis and inflammatory bowel disease.Biochemical Society transactions · 2021Review
- Roles of IL-25 in Type 2 Inflammation and Autoimmune Pathogenesis.Frontiers in immunology · 2021Review
- Therapeutic Effect of Mesenchymal Stem Cells in Ulcerative Colitis: A Review on Achievements and Challenges.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the influence of IL-25 on the capacity of mesenchymal stem cells (MSCs) to induce intestinal epithelial cell regeneration.
methodsThe CD4
resultsThe CD4
conclusionIL-25R is involved in Th-related mucosal inflammation and proliferation of intestinal stem cells in IBD. IL-25 enhances the capacity of MSC to induce intestinal epithelial cell regeneration, and MSC therapy with IL-25 may be a new direction for IBD treatment.
Indexed as
Identifiers
29312486PMC5752884W2922161743What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.